| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008
|
VanDenburgh, Amanda
|
|
2008
|
5 |
3 |
p. 490-495
|
artikel
|
| 2 |
Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease
|
Fisher, Abraham
|
|
2008
|
5 |
3 |
p. 433-442
|
artikel
|
| 3 |
Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease
|
Fisher, Abraham
|
|
2008
|
5 |
3 |
p. 433-442
10 p.
|
artikel
|
| 4 |
Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease
|
Fisher, Abraham
|
|
|
5 |
3 |
p. 433-442
|
artikel
|
| 5 |
Contents
|
|
|
2008
|
5 |
3 |
p. A2-A3
nvt p.
|
artikel
|
| 6 |
Contents
|
|
|
|
5 |
3 |
p. A2-A3
|
artikel
|
| 7 |
Editorial Board
|
|
|
2008
|
5 |
3 |
p. A1-
1 p.
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
5 |
3 |
p. A1
|
artikel
|
| 9 |
5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease
|
Upton, Neil
|
|
2008
|
5 |
3 |
p. 458-469
|
artikel
|
| 10 |
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
|
Upton, Neil
|
|
2008
|
5 |
3 |
p. 458-469
12 p.
|
artikel
|
| 11 |
5-HT6 Receptor Antagonists as Novel Cognitive Enhancing Agents for Alzheimer's Disease
|
Upton, Neil
|
|
|
5 |
3 |
p. 458-469
|
artikel
|
| 12 |
Inhibition and modulation of γ-secretase for Alzheimer’s disease
|
Wolfe, Michael S.
|
|
2008
|
5 |
3 |
p. 391-398
|
artikel
|
| 13 |
Inhibition and Modulation of γ-Secretase for Alzheimer's Disease
|
Wolfe, Michael S.
|
|
2008
|
5 |
3 |
p. 391-398
8 p.
|
artikel
|
| 14 |
Inhibition and Modulation of γ-Secretase for Alzheimer's Disease
|
Wolfe, Michael S.
|
|
|
5 |
3 |
p. 391-398
|
artikel
|
| 15 |
Ketone bodies as a therapeutic for Alzheimer’s disease
|
Henderson, Samuel T.
|
|
2008
|
5 |
3 |
p. 470-480
|
artikel
|
| 16 |
Ketone Bodies as a Therapeutic for Alzheimer's Disease
|
Henderson, Samuel T.
|
|
2008
|
5 |
3 |
p. 470-480
11 p.
|
artikel
|
| 17 |
Ketone Bodies as a Therapeutic for Alzheimer's Disease
|
Henderson, Samuel T.
|
|
|
5 |
3 |
p. 470-480
|
artikel
|
| 18 |
Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease
|
Bateman, Randall J.
|
|
2008
|
5 |
3 |
p. 381-390
|
artikel
|
| 19 |
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
|
Bateman, Randall J.
|
|
2008
|
5 |
3 |
p. 381-390
10 p.
|
artikel
|
| 20 |
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
|
Bateman, Randall J.
|
|
|
5 |
3 |
p. 381-390
|
artikel
|
| 21 |
New therapeutic targets in the neurovascular pathway in Alzheimer’s disease
|
Zlokovic, Berislav V.
|
|
2008
|
5 |
3 |
p. 409-414
|
artikel
|
| 22 |
New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease
|
Zlokovic, Berislav V.
|
|
2008
|
5 |
3 |
p. 409-414
6 p.
|
artikel
|
| 23 |
New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease
|
Zlokovic, Berislav V.
|
|
|
5 |
3 |
p. 409-414
|
artikel
|
| 24 |
Novel therapeutics for Alzheimer’s disease
|
Tanzi, Rudolph E.
|
|
2008
|
5 |
3 |
p. 377-380
|
artikel
|
| 25 |
Novel Therapeutics for Alzheimer's Disease
|
Tanzi, Rudolph E.
|
|
2008
|
5 |
3 |
p. 377-380
4 p.
|
artikel
|
| 26 |
Novel Therapeutics for Alzheimer's Disease
|
Tanzi, Rudolph E.
|
|
|
5 |
3 |
p. 377-380
|
artikel
|
| 27 |
Poster Abstract #6: Absorption, Distribution, Metabolism, and Excretion of 14C-labeled Nebicapone (BIA 3-202) and Metabolites
|
Almeida, Luis
|
|
2008
|
5 |
3 |
p. 492-
1 p.
|
artikel
|
| 28 |
Poster Abstract #6: Absorption, Distribution, Metabolism, and Excretion of 14C-labeled Nebicapone (BIA 3-202) and Metabolites
|
Almeida, Luis
|
|
|
5 |
3 |
p. 492
|
artikel
|
| 29 |
Poster Abstract #12: Brain and Plasma Pharmacokinetics of Three Dopamine Transporter (DAT)-Selective Blockers After Administration of a Range of Single Oral Doses in Conscious Mice
|
Cusack, Noel J.
|
|
2008
|
5 |
3 |
p. 494-
1 p.
|
artikel
|
| 30 |
Poster Abstract #12: Brain and Plasma Pharmacokinetics of Three Dopamine Transporter (DAT)-Selective Blockers After Administration of a Range of Single Oral Doses in Conscious Mice
|
Cusack, Noel J.
|
|
|
5 |
3 |
p. 494
|
artikel
|
| 31 |
Poster Abstract #11: Brain Microdialysate and Plasma Concentrations of Inosine During Intravenous Inosine Infusion in Conscious Rats
|
Cusack, Noel
|
|
2008
|
5 |
3 |
p. 494-
1 p.
|
artikel
|
| 32 |
Poster Abstract #11: Brain Microdialysate and Plasma Concentrations of Inosine During Intravenous Inosine Infusion in Conscious Rats
|
Cusack, Noel
|
|
|
5 |
3 |
p. 494
|
artikel
|
| 33 |
Poster Abstract #1: Clinically Meaningful Differences of the Ashworth Scale in Post-Stroke Upper Limb Spasticity
|
VanDenburgh, Amanda
|
|
2008
|
5 |
3 |
p. 490-
1 p.
|
artikel
|
| 34 |
Poster Abstract #1: Clinically Meaningful Differences of the Ashworth Scale in Post-Stroke Upper Limb Spasticity
|
VanDenburgh, Amanda
|
|
|
5 |
3 |
p. 490
|
artikel
|
| 35 |
Poster Abstract #4: Development of Long-Duration Accelerometry for Use in Clinical Trials of Essential Tremor
|
Nahab, Fatta
|
|
2008
|
5 |
3 |
p. 491-
1 p.
|
artikel
|
| 36 |
Poster Abstract #4: Development of Long-Duration Accelerometry for Use in Clinical Trials of Essential Tremor
|
Nahab, Fatta
|
|
|
5 |
3 |
p. 491
|
artikel
|
| 37 |
Poster Abstract #8: Effect of Nebicapone (BIA 3-202) on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects
|
Almeida, Luis
|
|
2008
|
5 |
3 |
p. 492-493
2 p.
|
artikel
|
| 38 |
Poster Abstract #8: Effect of Nebicapone (BIA 3-202) on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects
|
Almeida, Luis
|
|
|
5 |
3 |
p. 492-493
|
artikel
|
| 39 |
Poster Abstract #9: Influence of the Personality Trait Anxiety on Adverse Non-Drug-Related Symptoms
|
Almeida, Luis
|
|
2008
|
5 |
3 |
p. 493-
1 p.
|
artikel
|
| 40 |
Poster Abstract #9: Influence of the Personality Trait Anxiety on Adverse Non-Drug-Related Symptoms
|
Almeida, Luis
|
|
|
5 |
3 |
p. 493
|
artikel
|
| 41 |
Poster Abstract #13: Interactive Voice Response Diary and Objective Myotonia Measurement as Endpoints for Clinical Trials in Nondystrophic Interactive Voice Response Diary and Objective Myotonia Measurement as Endpoints for Clinical Trials in Nondystrophic Myotonia
|
Barohn, Richard
|
|
2008
|
5 |
3 |
p. 494-495
2 p.
|
artikel
|
| 42 |
Poster Abstract #13: Interactive Voice Response Diary and Objective Myotonia Measurement as Endpoints for Clinical Trials in Nondystrophic Interactive Voice Response Diary and Objective Myotonia Measurement as Endpoints for Clinical Trials in Nondystrophic Myotonia
|
Barohn, Richard
|
|
|
5 |
3 |
p. 494-495
|
artikel
|
| 43 |
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis
|
Bakshi, Rohit
|
|
2008
|
5 |
3 |
p. 495-
1 p.
|
artikel
|
| 44 |
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis
|
Bakshi, Rohit
|
|
|
5 |
3 |
p. 495
|
artikel
|
| 45 |
Poster Abstract #3: mGluR5 Activation Reduces Microglial-Mediated Neurotoxicity in Vitro and Improves Outcome After Experimental Traumatic Brain Injury
|
Loane, David J.
|
|
2008
|
5 |
3 |
p. 490-491
2 p.
|
artikel
|
| 46 |
Poster Abstract #3: mGluR5 Activation Reduces Microglial-Mediated Neurotoxicity in Vitro and Improves Outcome After Experimental Traumatic Brain Injury
|
Loane, David J.
|
|
|
5 |
3 |
p. 490-491
|
artikel
|
| 47 |
Poster Abstract #15: MRI Measurement of Whole Spinal Cord Volume at 3T: Reproducibility and Relevance to Multiple Sclerosis
|
Arora, Ashish
|
|
2008
|
5 |
3 |
p. 495-
1 p.
|
artikel
|
| 48 |
Poster Abstract #15: MRI Measurement of Whole Spinal Cord Volume at 3T: Reproducibility and Relevance to Multiple Sclerosis
|
Arora, Ashish
|
|
|
5 |
3 |
p. 495
|
artikel
|
| 49 |
Poster Abstract #5: NIH Roadmap Molecular Libraries Screening Centers Network
|
Li, Ingrid
|
|
2008
|
5 |
3 |
p. 491-492
2 p.
|
artikel
|
| 50 |
Poster Abstract #5: NIH Roadmap Molecular Libraries Screening Centers Network
|
Li, Ingrid
|
|
|
5 |
3 |
p. 491-492
|
artikel
|
| 51 |
Poster Abstract #7: Pharmacokinetic-Pharmacodynamic Interaction Between Nebicapone (BIA 3-202) and Controlled-release Levodopa/Benserazide (Madopar HBS 125)
|
Almeida, Luis
|
|
2008
|
5 |
3 |
p. 492-
1 p.
|
artikel
|
| 52 |
Poster Abstract #7: Pharmacokinetic-Pharmacodynamic Interaction Between Nebicapone (BIA 3-202) and Controlled-release Levodopa/Benserazide (Madopar HBS 125)
|
Almeida, Luis
|
|
|
5 |
3 |
p. 492
|
artikel
|
| 53 |
Poster Abstract #10: Prevalence of Adverse Non-drug-related Symptoms in Volunteers to Phase I Studies and in Normal Population
|
Almeida, Luis
|
|
2008
|
5 |
3 |
p. 493-
1 p.
|
artikel
|
| 54 |
Poster Abstract #10: Prevalence of Adverse Non-drug-related Symptoms in Volunteers to Phase I Studies and in Normal Population
|
Almeida, Luis
|
|
|
5 |
3 |
p. 493
|
artikel
|
| 55 |
Poster Abstract #2: Surrogate Completion of the Treatment Satisfaction Questionnaire for Medication for a Trial of Corticosteroids in Duchenne Muscular Dystrophy
|
Herr, Barbara E.
|
|
2008
|
5 |
3 |
p. 490-
1 p.
|
artikel
|
| 56 |
Poster Abstract #2: Surrogate Completion of the Treatment Satisfaction Questionnaire for Medication for a Trial of Corticosteroids in Duchenne Muscular Dystrophy
|
Herr, Barbara E.
|
|
|
5 |
3 |
p. 490
|
artikel
|
| 57 |
PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease
|
Landreth, Gary
|
|
2008
|
5 |
3 |
p. 481-489
|
artikel
|
| 58 |
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
|
Landreth, Gary
|
|
2008
|
5 |
3 |
p. 481-489
9 p.
|
artikel
|
| 59 |
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
|
Landreth, Gary
|
|
|
5 |
3 |
p. 481-489
|
artikel
|
| 60 |
β-Secretase as a therapeutic target for Alzheimer’s disease
|
Ghosh, Arun K.
|
|
2008
|
5 |
3 |
p. 399-408
|
artikel
|
| 61 |
β-Secretase as a Therapeutic Target for Alzheimer's Disease
|
Ghosh, Arun K.
|
|
2008
|
5 |
3 |
p. 399-408
10 p.
|
artikel
|
| 62 |
β-Secretase as a Therapeutic Target for Alzheimer's Disease
|
Ghosh, Arun K.
|
|
|
5 |
3 |
p. 399-408
|
artikel
|
| 63 |
Targeting β-amyloid pathology in Alzheimer’s disease with Aβ immunotherapy
|
Nitsch, Roger M.
|
|
2008
|
5 |
3 |
p. 415-420
|
artikel
|
| 64 |
Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy
|
Nitsch, Roger M.
|
|
2008
|
5 |
3 |
p. 415-420
6 p.
|
artikel
|
| 65 |
Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy
|
Nitsch, Roger M.
|
|
|
5 |
3 |
p. 415-420
|
artikel
|
| 66 |
Tau-based treatment strategies in neurodegenerative diseases
|
Schneider, Anja
|
|
2008
|
5 |
3 |
p. 443-457
|
artikel
|
| 67 |
Tau-Based Treatment Strategies in Neurodegenerative Diseases
|
Schneider, Anja
|
|
2008
|
5 |
3 |
p. 443-457
15 p.
|
artikel
|
| 68 |
Tau-Based Treatment Strategies in Neurodegenerative Diseases
|
Schneider, Anja
|
|
|
5 |
3 |
p. 443-457
|
artikel
|
| 69 |
Therapeutics for Alzheimer’s disease based on the metal hypothesis
|
Bush, Ashley I.
|
|
2008
|
5 |
3 |
p. 421-432
|
artikel
|
| 70 |
Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis
|
Bush, Ashley I.
|
|
2008
|
5 |
3 |
p. 421-432
12 p.
|
artikel
|
| 71 |
Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis
|
Bush, Ashley I.
|
|
|
5 |
3 |
p. 421-432
|
artikel
|
Tijdschrift beschrijving